ORTHOCELL ORD
Orthocell's Remplir Device Used in 23 Ukrainian Soldier Surgeries, Validating Field Utility
Orthocell's Remplir validated after 23 Ukrainian surgeries, boosting defence-market traction and global expansion; HY26 revenue +49%, cash ~A$49m.
Orthocell Appoints Exclusive Remplir Distributor Ahead of UK Rollout
Orthocell names LEDA Orthopaedics exclusive UK distributor for Remplir ahead of regulatory approval, signaling rapid UK rollout and market prep.
Orthocell Reports Accelerated Adoption of Remplir Nerve Repair Technology by Australian Surgeons
Orthocell (ASX: OCC) has confirmed accelerating adoption of lead product Remplir by Australian urologists, with the product so far used in approximately 100 prostate cancer surgeries nationwide to assist in post-surgical complications from peripheral nerve injury.
Orthocell Appoints First Canadian Distributor For Remplir Collagen Nerve Wrap
Orthocell (ASX: OCC) has appointed the first Canadian distributor for its innovative Remplir collagen nerve wrap ahead of an official in-country launch next month. The undisclosed distributor reportedly has a wealth of expertise in the nerve, spine, and orthopaedic implant markets, with established links in the nation’s healthcare sector to drive product adoption. Orthocell has secured […]